Oova, Inc.

Oova, Inc. manufactures at-home hormone-tracking test kits and digital health platform for fertility and perimenopause management. The company's core product is a urine-based test strip that quantitatively measures luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite). Users scan test strips with a smartphone camera; proprietary AI-powered software analyzes hormone levels in real time and delivers personalized insights via a mobile app. Oova claims 99% lab-accuracy correlation to blood testing. The platform includes HIPAA-compliant provider-reporting tools enabling seamless data sharing with healthcare providers; 400+ clinics have integrated Oova. The company offers two guided product lines: Fertility Hormone Kit (for ovulation tracking and conception planning) and Perimenopause Hormone Kit (for tracking hormone fluctuations during midlife transitions). Clinical validation by Mount Sinai physicians; recognized by American Society for Reproductive Medicine (ASRM), American College of Obstetricians and Gynecologists (ACOG), and The Menopause Society. The Oova Membership tier includes 1:1 expert consultations, peer community access, and 30% discounts on test kits. The app functions as a free symptom tracker independently of test strips. Target markets include women trying to conceive, those with PCOS or irregular cycles, perimenopause patients, and those optimizing reproductive health through cycle syncing.